Du är här

2016-02-08

DBV Technologies: DBV Technologies to Present at the LEERINK Partners 5th Annual Global Healthcare Conference

--------------------------------------
| Press Release |
| |
|Montrouge, France, February 8, 2016 |
--------------------------------------

DBV Technologies to Present at the LEERINK Partners 5thAnnual Global Healthcare ConferenceDBV Technologies, (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market:
DBVT), a clinical-stage specialty biopharmaceutical company, today announced
that Charles Ruban, Chief Commercial Officer, and Susanna Mesa, Vice
President of Finance, Investor Relations&Strategy, will present at LEERINK
Partners 5thAnnual Global Healthcare Conference on Wednesday, February 10th,
2016 at

3:55 pm ET at the Waldorf Astoria Hotel in New York, NY.

A live audio webcast of the presentation will be available on the Investor
Relations section of the Company's
website,http://www.dbv-technologies.com/en/investor-relations. A replay will
also be available 48 hours after the event.

About DBV Technologies

DBV Technologies is developing Viaskin®, an innovative new approach to the
treatment of allergies - a major public health issue that has been increasing
in prevalence. DBV Technologies, incorporated in France in 2002, has
developed a proprietary, patented technology for administering an allergen to
intact skin while avoiding transfer to the blood, and thus lowering the risk
of a systemic, allergic reaction in the event of accidental exposure. DBV
Technologies is focusing on food allergies, including milk and peanut, for
which there are currently no effective treatments. DBV Technologies has
designed two products candidates: Viaskin® Peanut and Viaskin® Milk. The
clinical development program for Viaskin® Peanut has received Fast Track
designation and Breakthrough Therapy designation from the U.S. Food and Drug
Administration.

DBV Technologies shares are traded on segment B of Euronext Paris (Ticker:
DBV, ISIN code: FR0010417345) and on the Nasdaq Stock Market in the form of
American Depositary Shares (each representing one-half of one ordinary share)
(Ticker: DBVT). For more information on DBV Technologies, please visit our
website:www.dbv-technologies.com

----------------------------------------------------------------------------------------------------
| DBV Technologies Contacts |
| Nathalie Donne Susanna Mesa |
| |
| VP of Finance, Investor Relations&Strategy |
|Director, Corporate Communication&Business Development Tel. : +1 212-271-0861 |
| susanna.mesa@dbv-technologies.com |
|Tel. : +33 (0)1 55 42 78 72 |
| |
|nathalie.donne@dbv-technologies.com |
| DBV Technologies Media Contacts US&Europe |
| Marion Janic Caroline Carmagnol |
| |
| |
|Rooney&Associates Alize RP - Relation Presse |
| |
|Tel. : +1 212-223-4017 Tel. : +33 (0)6 64 18 99 59 |
|mjanic@rooneyco.com caroline@alizerp.com |
----------------------------------------------------------------------------------------------------
PDF Version
http://hugin.info/156437/R/1984165/727364.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: DBV Technologies via Globenewswire

HUG#1984165

Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.